GANYMED PHARMACEUTICALS
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.
GANYMED PHARMACEUTICALS
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2001-01-01
Address:
Mainz, Rheinland-Pfalz, Germany
Country:
Germany
Website Url:
http://www.ganymed.ag
Total Employee:
11+
Status:
Closed
Contact:
49 6131 1440 100
Email Addresses:
[email protected]
Total Funding:
212.7 M USD
Technology used in webpage:
MarkMonitor DNS 040 Hosting
Current Advisors List
Current Employees Featured
Founder
Investors List
Future Capital
Future Capital investment in Series E - Ganymed Pharmaceuticals
MIG
MIG investment in Series E - Ganymed Pharmaceuticals
ATS Beteiligungsverwaltung
ATS Beteiligungsverwaltung investment in Series E - Ganymed Pharmaceuticals
FCPB
FCPB investment in Series E - Ganymed Pharmaceuticals
Future Capital
Future Capital investment in Series D - Ganymed Pharmaceuticals
MIG
MIG investment in Series D - Ganymed Pharmaceuticals
ATS Beteiligungsverwaltung
ATS Beteiligungsverwaltung investment in Series D - Ganymed Pharmaceuticals
ATS Beteiligungsverwaltung
ATS Beteiligungsverwaltung investment in Series C - Ganymed Pharmaceuticals
VI Partners
VI Partners investment in Series C - Ganymed Pharmaceuticals
Ingro Finanz AG
Ingro Finanz AG investment in Series C - Ganymed Pharmaceuticals
More informations about "Ganymed Pharmaceuticals"
Ganymed Pharmaceuticals - Crunchbase Company …
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic …See details»
Astellas Completes Acquisition of Ganymed Pharmaceuticals
Tokyo, December 21, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has completed the acquisition of Ganymed …See details»
Ganymed Pharmaceuticals AG - life-sciences-germany.com
Jan 1, 2001 Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal …See details»
GANYMED Pharmaceuticals AG - VentureRadar
GANYMED Pharmaceuticals AG is a leading biopharmaceutical company offering smart antibody therapeutics for ideal targets in solid cancers. The Company’s discovery engine is one of the …See details»
Ganymed Pharmaceuticals AG - Ownership and Business Overview …
Oct 28, 2016 Ganymed Pharmaceuticals AG was founded in 2001. Life Science M&A Summary in 2016 Out of 60 sectors in the Mergr database, life science ranked 8 in number of deals in …See details»
Ganymed Pharmaceuticals AG - Mainz, Germany - bionity.com
GANYMED lead antibodies show excellent efficacy and safety in mouse tumor models. GANYMED Pharmaceuticals AG announced that several monoclonal lead antibodies directed …See details»
Ganymed Pharmaceuticals GmbH, Mainz, Germany - North Data
1 Apr 2005 as Ganymed Pharmaceuticals AG Public funding (€1,116,464): BioChancePLUS-2: Expansion and use of Microgate technology to characterize multiple sclerosis-associated …See details»
Organization | Ganymed Pharmaceuticals AG
Ganymed Pharmaceuticals AG Report issue. For profit Phase 1 Phase 2. Founded: Mainz Germany (2001 ... Organization Overview. First Clinical Trial. 2009 NCT00909025. First …See details»
Ganymed Pharmaceuticals | VentureRadar
Ganymed Pharmaceuticals AG is a leading biopharmaceutical company offering smart antibody therapies for ideal targets in solid cancers. The company's discovery engine is one of the …See details»
Ganymed Pharmaceuticals - 2025 Company Profile - Tracxn
Mar 23, 2025 Ganymed Pharmaceuticals - Developer of antibody-based drugs for the treatment of solid cancers. Acquired by Astellas Pharma. Raised a total funding of $212M over 6 rounds …See details»
Ganymed Pharmaceuticals AG (Ganymed …
3.5.Zolbetuximab（安斯泰来制药公司） Zolbetuximab（VYLOY，zolbetuximab-clzb）是一种嵌合IgG1κ抗体，靶向Claudin 18.2（CLDN18.2），最初由Ganymed Pharmaceuticals AG开发。安斯泰来于2016年收购了Ganymed。CLDN18.2是 …See details»
Ganymed Pharmaceuticals GmbH, Mainz - North Data
Ganymed Pharmaceuticals GmbH, Mainz, Amtsgericht Mainz HRB 47318: Gewinn, Förderung, Umsatz, Mitarbeiter, Netzwerk, Wirtschaftsinfos. Home Premium Service Data Service …See details»
Ganymed Pharmaceuticals AG - Drug pipelines, Patents, Clinical …
Literatures (Medical) associated with Ganymed Pharmaceuticals AG 01 Dec 2018 · Journal of nanobiotechnology Q2 · ENGINEERING & TECHNOLOGY Enhanced stability of a chimeric …See details»
GANYMED Pharmaceuticals AG | VentureRadar
GANYMED Pharmaceuticals AG is a leading biopharmaceutical company offering smart antibody therapeutics for ideal targets in solid cancers. The Company’s discovery engine is one of the …See details»
Ganymed Pharmaceuticals - PitchBook
Ganymed Pharmaceuticals General Information Description. Developer of antibody therapeutics for the treatment of solid cancers. The company focuses on building a pipeline of antibody …See details»
Ganymed Pharmaceuticals | Biotechnology - The Pharmaletter
Ganymed Pharmaceuticals AG is a German biotech company focusing on the development of a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs) for the treatment of …See details»
European Business Development Conference - BIO Deutschland
Website: www.ganymed.ag Existing co-operations: Request for co-operations: Ganymed Pharmaceuticals AG is a leading biopharmaceutical company focusing on the development of …See details»
Ganymed Pharmaceuticals - EquityNet
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal …See details»
Ganymed Pharmaceuticals Closes Significant Financing Round
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal …See details»
Ganymed Pharmaceuticals - CoBee Company Profile & Funding …
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal …See details»